Key Takeaway: Nurix is focused on developing innovative therapies targeting cancer and autoimmune diseases through protein degradation. The company emphasizes its commitment to translating scientific insights into effective treatments. The article highlights their multi-modal portfolio, which includes both wholly owned and partnered assets.
Price reaction · baseline $23.94 (2024-08-21T17:58:00.000Z) · hit during market hours · clean, no other NRIX news in the window
day 0 close · peak
-0.1%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.